Literature DB >> 30343320

Molecular pathways of nonalcoholic fatty liver disease development and progression.

Fernando Bessone1, María Valeria Razori2, Marcelo G Roma3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic syndrome. It represents a wide spectrum of histopathological abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with or without fibrosis and, eventually, cirrhosis and hepatocellular carcinoma. While hepatic simple steatosis seems to be a rather benign manifestation of hepatic triglyceride accumulation, the buildup of highly toxic free fatty acids associated with insulin resistance-induced massive free fatty acid mobilization from adipose tissue and the increased de novo hepatic fatty acid synthesis from glucose acts as the "first hit" for NAFLD development. NAFLD progression seems to involve the occurrence of "parallel, multiple-hit" injuries, such as oxidative stress-induced mitochondrial dysfunction, endoplasmic reticulum stress, endotoxin-induced, TLR4-dependent release of inflammatory cytokines, and iron overload, among many others. These deleterious factors are responsible for the triggering of a number of signaling cascades leading to inflammation, cell death, and fibrosis, the hallmarks of NASH. This review is aimed at integrating the overwhelming progress made in the characterization of the physiopathological mechanisms of NAFLD at a molecular level, to better understand the factor influencing the initiation and progression of the disease.

Entities:  

Keywords:  Hepatocellular death; Lipotoxicity; Liver fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30343320     DOI: 10.1007/s00018-018-2947-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  282 in total

1.  SOCS-3 is an insulin-induced negative regulator of insulin signaling.

Authors:  B Emanuelli; P Peraldi; C Filloux; D Sawka-Verhelle; D Hilton; E Van Obberghen
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

Review 2.  Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.

Authors:  S L Friedman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

Review 3.  Cytokines and fibrogenesis.

Authors:  S L Friedman
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 4.  Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.

Authors:  E M Brunt
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

Review 5.  Cellular mechanisms of insulin resistance.

Authors:  G I Shulman
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 6.  Cell death induced by the Fas/Fas ligand pathway and its role in pathology.

Authors:  P Waring; A Müllbacher
Journal:  Immunol Cell Biol       Date:  1999-08       Impact factor: 5.126

7.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

8.  Association of nonalcoholic fatty liver disease with insulin resistance.

Authors:  G Marchesini; M Brizi; A M Morselli-Labate; G Bianchi; E Bugianesi; A J McCullough; G Forlani; N Melchionda
Journal:  Am J Med       Date:  1999-11       Impact factor: 4.965

Review 9.  Fatty acid import into mitochondria.

Authors:  J Kerner; C Hoppel
Journal:  Biochim Biophys Acta       Date:  2000-06-26

10.  Mitochondrial abnormalities in non-alcoholic steatohepatitis.

Authors:  S H Caldwell; R H Swerdlow; E M Khan; J C Iezzoni; E E Hespenheide; J K Parks; W D Parker
Journal:  J Hepatol       Date:  1999-09       Impact factor: 25.083

View more
  102 in total

1.  Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.

Authors:  Amanda Hanson; Ignazio S Piras; Danielle Wilhelmsen; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Cytokine       Date:  2019-07-25       Impact factor: 3.861

2.  A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Authors:  Md Abdul Hye Khan; Jurema Schmidt; Anna Stavniichuk; John D Imig; Daniel Merk
Journal:  Biochem Pharmacol       Date:  2019-05-23       Impact factor: 5.858

Review 3.  Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease.

Authors:  Pankaj Prasun; Ilona Ginevic; Kimihiko Oishi
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 4.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

5.  Nonalcoholic fatty liver disease in CLOCK mutant mice.

Authors:  Xiaoyue Pan; Joyce Queiroz; M Mahmood Hussain
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

6.  The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice.

Authors:  Minjuan Ma; Rui Duan; Lulu Shen; Mengting Liu; Yaya Ji; Hao Zhou; Changxian Li; Tingming Liang; Xiangcheng Li; Li Guo
Journal:  J Lipid Res       Date:  2020-03-30       Impact factor: 5.922

Review 7.  Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease.

Authors:  Christina T Saed; Seyed Amirhossein Tabatabaei Dakhili; John R Ussher
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-03

8.  GPR84 Is Essential for the Taste of Medium Chain Saturated Fatty Acids.

Authors:  Yan Liu; Han Xu; Naima Dahir; Ashley Calder; Fangjun Lin; Timothy A Gilbertson
Journal:  J Neurosci       Date:  2021-05-03       Impact factor: 6.167

9.  Nonalcoholic Steatohepatitis Modifies Serum Iron-Related Variables in Patients with Morbid Obesity.

Authors:  Anna Hernández-Aguilera; Núria Casacuberta; Helena Castañé; Montserrat Fibla; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Marta París; Fàtima Sabench; Daniel Del Castillo; Gerard Baiges-Gaya; Elisabet Rodríguez-Tomàs; Teresa Sans; Jordi Camps; Jorge Joven
Journal:  Biol Trace Elem Res       Date:  2021-02-08       Impact factor: 3.738

10.  A human liver chimeric mouse model for non-alcoholic fatty liver disease.

Authors:  Beatrice Bissig-Choisat; Michele Alves-Bezerra; Barry Zorman; Scott A Ochsner; Mercedes Barzi; Xavier Legras; Diane Yang; Malgorzata Borowiak; Adam M Dean; Robert B York; N Thao N Galvan; John Goss; William R Lagor; David D Moore; David E Cohen; Neil J McKenna; Pavel Sumazin; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2021-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.